Novel Method Identifies Prostate Cancer Patients Who Require Aggressive Treatments

Novel Method Identifies Prostate Cancer Patients Who Require Aggressive Treatments
Researchers at Cedar-Sinai have developed a novel way to identify which prostate cancer patients will develop aggressive types of the disease based on the genes that are activated in each individual tumor. The study, "Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome," published in Cancer Research, divides prostate cancer patients into three distinct subtypes, may help clinicians provide more effective, tailored treatments to each patient. "These findings raise the possibility that by determining the gene expression profile of a patient's tumor, physicians may be able to identify aggressive disease at the outset of diagnosis and start treatment earlier," Sungyong You, PhD, an instructor in the Cedars-Sinai Department of Surgery and the first author of the study, said in a press release. Currently, researchers rely on the Gleason grade to determine which cancers will develop into dangerous forms of the disease. This score ranks the cancer cells from 2 to 10 based on how similar they are to normal prostate cells. The higher the grade, the higher the risk of patients having a poor outcome. But this method is not accurate enough, and some patients may not receive the appropriate treatments, such as radiation, hormone therapy, or removal of the prostate, in a timely manner, while others may be receiving unnecessary treatm
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *